- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
In-cell molecular sieve from protein crystal February 14th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017
Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017